Enzymatica
2.00 SEK
+4.71 %
Less than 1K followers
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+4.71 %
+3.09 %
+5.26 %
+5.54 %
-13.42 %
+23.46 %
-27.42 %
-85.90 %
-64.99 %
Enzymatica is a life science company that develops and sells medical devices against infectious diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray, which can prevent colds and shorten the duration of the illness. The product has been launched in several markets and the strategy is to expand to more markets through partners. The head office is located in Lund.
Read moreMarket cap
485.47M SEK
Turnover
154.03K SEK
Revenue
53.9M
EBIT %
-95.3 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28/4
2026
Interim report Q1'26
7/5
2026
General meeting '26
16/7
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Enzymatica AB: Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion
Enzymatica AB: Enzymatica appoints Acting CFO during transition period
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools